A Single Dose Study of the Pharmacodynamics, Tolerability, and Pharmacokinetics of GAL-054

A Single Dose Study of the Pharmacodynamics, Tolerability, and Pharmacokinetics of GAL-054 - Single Dose PD and Tolerability of GAL-054

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON37672

Enrollment

Registered

2011-10-07

Start date

2011-10-17

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breath disorders

Interventions

24-36 healthy male and female volunteers will participate in this 2-part trial. Part 1 is a 7-period study. During the first 6 periods approximately 12 subjects will receive a single intravenous inf

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteer 18-45 years

Exclusion criteria

Exclusion criteria: Clinical significant abnormalities

Design outcomes

Primary

Measure	Time frame
The pharmacodynamic effects of GAL-054 in comparison to doxapram in healthy subjects	—

Secondary

Measure	Time frame
Tolerability and pharmacokinetics	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)